- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07643467
Fluorescent Probe for Assessment of Renal Elimination (FLARE)
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The majority of acutely ill patients exhibit changes in renal function due to inflammation, increased solute generation, and iatrogenic factors such as fluid resuscitation and vasopressors. The pharmacokinetics of renally eliminated medications (eg. levetiracetam, cefepime, vancomycin) are frequently affected by inflammatory processes despite normal estimations in creatinine clearance resulting in suboptimal serum drug concentrations and therapeutic failure. Despite the prevalence of fluctuations in renal function in acute illness, real-time assessment is limited to monitoring of serum biomarkers such as creatinine and cystatin C, as well as urine output, which typically lag behind important changes in function. Furthermore, use of creatinine clearance equations based on anthropomorphic data correlates poorly with actual renal function, potentially misleading clinicians as to the progression of disease and the need for dose adjustment of important medications in this vulnerable population.
Limitations of current approaches for evaluating renal function in the acutely ill Estimation of GFR or creatinine clearance can be accomplished by numerous equations, the majority of which have been validated in non-critically ill adults, usually with a relatively high percent of patients with chronic kidney disease. These equations are often not accurate in patients with acutely worsening renal function. Likewise, while these equations are helpful for categorizing renal function and assessing appropriate medication dosing in otherwise healthy, ambulatory patients. Under-prediction of creatinine clearance values leads clinicians to consistently under-dose critical medications such as beta-lactam antibiotics, vancomycin, or antiseizure medications such as levetiracetam.
Proactive measurement of creatinine clearance can provide a more accurate depiction of GFR but is fraught with complications. Iohexol serum concentrations correlate well with GFR, but requires intravenous administration of iohexol, which has a small risk of infusion reaction and hypersensitivity, and serial blood samples. Measured urine creatinine clearance is also feasible but inconvenient in most hospitalized patients. mClCr requires bladder catheterization for accurate urine volume, consistent storage on ice for the duration of collection (between 8 and 24 hours), and prompt delivery of the large volume container to the local laboratory for creatinine analysis. Each of these criteria introduce variability into the measurement and are often unnoticed or undocumented, introducing inaccuracy into the mClCr values. The lack of a real-time, accurate assessment of creatinine clearance in the acutely ill population is a gap in practice and represents a resolvable problem in the process of individualized and precision dosing of medications in this vulnerable and high-risk population.
This study represents an important innovation in advancing the understanding of fluctuations in renal function during acute illness. The current study will validate the safety of transdermal GFR monitoring to provide real-time measurement of renal function in patients with stable renal function. Further, the reliability of transdermal GFR monitoring will be compared to current standards of renal function assessment. The results of this study will advance the field by validating the use of a real-time physiologic assessment of GFR rather than using labor intensive, invasive tests that may lag behind current renal function. Numerous important gaps remain with this new technology, including use primarily in the ambulatory, stable renal function populations. Thus, this study is potentially the first step in evaluating renal function across the acute care continuum.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Aaron Cook, PharmD
- Numéro de téléphone: 18592578444
- E-mail: amcook0@uky.edu
Lieux d'étude
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- UKHealthCare/University of Kentucky
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- 18-65 years old
- critically ill or acutely ill hospitalized patients admitted to the intensive care unit
- Stable/normal renal function
Exclusion Criteria:
- Prisoners
- Pregnant women
- Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr > 1.5x baseline)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: MediBeacon Transdermal Glomerular Filtration Rate (GFR) Monitoring
|
IV push of relmapirazin (Lumitrace) prior to use of the tGFR device
Small IV push bolus of iohexol as a probe for renal function will be administered prior to use of the tGFR device.
The tGFR monitor will be applied to the patient after relmapirazin bolus for measurement of GFR.
8-hour urine creatinine clearance collection will be performed during the study period to compare to tGFR & other renal function measures.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Transdermal Glomerular Filtration Rate (tGFR) Monitoring Accuracy
Délai: 8 Hours
|
Accuracy of transdermal glomerular filtration rate (GFR) monitoring compared with measured urine creatinine clearance.
|
8 Hours
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Relmapirazin Elimination Half-Life
Délai: 12 hours
|
Elimination half-life of Relmapirazin calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
|
12 hours
|
|
Iohexol Elimination Half-Life
Délai: 12 hours
|
Elimination half-life of Iohexol calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
|
12 hours
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Aaron M Cook, PharmD, University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science
- Directeur d'études: Juan-Carlos Aycinena, MD, University of Kentucky College of Medicine, Department of Nephrology
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Attributs de la maladie
- Conditions pathologiques, signes et symptômes
- Maladie critique
- Produits chimiques organiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Acides carboxyliques
- Hydrocarbures, aromatique
- Dérivés de benzène
- Acides, carbocyclique
- Benzoates
- Acides triiodobenzoïques
- Iodobenzoates
- Iohexol
- relmapirazine
Autres numéros d'identification d'étude
- 105008
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .